Clinical Trial Update: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial comparing BEZ235 (dactolisib) to Everolimus in advanced pancreatic neuroendocrine tumors was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• BEZ235 (dactolisib)
• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pancreatic Neuroendocrine Tumors (pNET) | Phase 2 | Status: TERMINATED | Results posted: 2016-04-07